Article

COVID-19: BELKIN Laser CEO offers company update

Author(s):

Alex Delaney-Gesing

Daria Lemann-Blumenthal, CEO of BELKIN Laser Ltd, provides an update on how the company's operations have continued to progress amid the coronavirus pandemic.

 

See more coronavirus coverage here

Related Videos
Bonnie An Henderson, MD, and EnVision Summit 2025 preview
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
Lorraine Provencher, MD, presenting slides
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Deb Ristvedt, DO's CIME 2024 Talk Highlights Innovations in Treating Glaucoma via the Trabecular Meshwork
Related Content
Iantrek, Inc. announces 1-Year outcomes from the CREST Registry for bio-interventional glaucoma treatment
December 13th 2024

Iantrek, Inc. announces 1-Year outcomes from the CREST Registry for bio-interventional glaucoma treatment

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Study highlights current and potential roles of AI in glaucoma diagnosis
December 7th 2024

Study highlights current and potential roles of AI in glaucoma diagnosis

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

BMI, tobacco, and alcohol: Roles in glaucoma progression examined in new study
November 28th 2024

BMI, tobacco, and alcohol: Roles in glaucoma progression examined in new study

SpyGlass Pharma completes enrollment in Phase I/II study of its long-term drug delivery platform for glaucoma and ocular hypertension
November 19th 2024

SpyGlass Pharma completes enrollment in Phase I/II study of its long-term drug delivery platform for glaucoma and ocular hypertension

© 2024 MJH Life Sciences

All rights reserved.